Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions

BMC Genomics

Volumn 13, Issue 1, 2012, Pages

  Cheng, Shu ^a   Prot, Jean Matthieu ^a   Leclerc, Eric ^a   Bois, Frédéric Y ^a,b  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Gene sets analysis; Hepatic zonation; Hepatocellular carcinoma; Pdms microfluidic biochips; Petri plates; Ubiquitination system

Indexed keywords

CYTOCHROME P450; PHOSPHOTRANSFERASE; BETA CATENIN; GLUTAMINE; PROTEIN KINASE; PROTEOME; UBIQUITIN;

ARTICLE; BIOCHIP; CARCINOMA CELL; CELL CULTURE; CELL CULTURE EQUIPMENT; CELL METABOLISM; CELL SPECIFICITY; CELL STRAIN HEPG2; CONTROLLED STUDY; DYNAMICS; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SET ENRICHMENT ANALYSIS; GENETIC ANALYSIS; HEPATIC ZONATION; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MICROFLUIDICS; PETRI DISH; PHENOTYPE; PROTEIN EXPRESSION; PROTEOMICS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION; CULTURE TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MICROFLUIDIC ANALYSIS; PATHOLOGY; TUMOR CELL LINE;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINE; HUMANS; LIVER NEOPLASMS; MICROFLUIDIC ANALYTICAL TECHNIQUES; PROTEIN KINASES; PROTEOME; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

EID: 84856376823     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-13-54     Document Type: Article

References (50)

1. Christoffels VM, Sassi H, Ruijter JM, Moorman AF, Grange T, Lamers WH. A mechanistic model for the development and maintenance of portocentral gradients in gene expression in the liver. Hepatology 1999, 29(4):1180-1192.
2. Gebhardt R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol Ther 1992, 53(3):275-354.
3. Jungermann K, Katz N. Functional specialization of different hepatocyte populations. Physiol Rev 1989, 69(3):708-764.
4. Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr 1996, 16:179-203.
5. Braeuning A, Schwarz M. β-Catenin as a multilayer modulator of zonal cytochrome P450 expression in mouse liver. Biological Chemistry 2009, 391(2/3):139-148.
6. Sheikh-Bahaei S, Maher JJ, Anthony Hunt C. Computational experiments reveal plausible mechanisms for changing patterns of hepatic zonation of xenobiotic clearance and hepatotoxicity. J Theor Biol 2010, 265(4):718-733.
7. Ierapetritou MG, Georgopoulos PG, Roth CM, Androulakis LP. Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational research. Clin Transl Sci 2009, 2(3):228-237.
8. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31(4):339-346.
9. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005, 25(2):212-225.
10. Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell 2006, 10(6):759-770.
11. Moriyama A, Kii I, Sunabori T, Kurihara S, Takayama I, Shimazaki M, Tanabe H, Oginuma M, Fukayama M, Matsuzaki Y, Saga Y, Kudo A. GFP transgenic mice reveal active canonical Wnt signal in neonatal brain and in adult liver and spleen. Genesis 2007, 45(2):90-100.
12. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82(2):373-428.
13. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999, 286(5438):309-312.
14. HuangFu W-C, Fuchs SY. Ubiquitination-Dependent Regulation of Signaling Receptors in Cancer. Genes & Cancer 2010, 1(7):725-734.
15. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004, 40:2217-2229.
16. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34(3):267-273.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550.
18. Thomas R, Gohlke JM, Stopper GF, Parham FM, Portier CJ. Choosing the right path: enhancement of biologically relevant sets of genes or proteins using pathway structure. Genome Biol 2009, 10(4):R44.
19. Guguen-Guillouzo C, Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods Mol Biol 2010, 640:1-40.
20. Vanhaecke T, Rogiers V. Hepatocyte cultures in drug metabolism and toxicological research and testing. Methods Mol Biol 2006, 320:209-227.
21. Griffith LG, Naughton G. Tissue engineering--current challenges and expanding opportunities. Science 2002, 295(5557):1009-1014.
22. Baudoin R, Corlu A, Griscom L, Legallais C, Leclerc E. Trends in the development of microfluidic cell biochips for in vitro hepatotoxicity. Toxicology in Vitro 2007, 21(4):535-544.
23. Prot JM, Aninat C, Griscom L, Razan F, Brochot C, Guillouzo CG, Legallais C, Corlu A, Leclerc E. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol Bioeng 2011, 108:1704-1715.
24. Huang R, Wallqvist A, Covell DG. Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen. Genomics 2006, 87(3):315-328.
25. Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006, 2(2):183-212.
26. Torre C, Perret C, Colnot S. Transcription dynamics in a physiological process: beta-catenin signaling directs liver metabolic zonation. Int J Biochem Cell Biol 2011, 43(2):271-278.
27. Fajans SS, Bell GI, Polonsky KS. Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young. New England Journal of Medicine 2001, 345(13):971-980.
28. Murray GI, Paterson PJ, Weaver RJ, Ewen SWB, Melvin WT, Burke MD. The expression of cytochrome P-450, epoxide hydrolase, and glutathione s-transferase in hepatocellular carcinoma. Cancer 1993, 71(1):36-43.
29. Rendic S, Guengerich FP. Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010, 11(1):4-84.
30. Lamba JK, Chen X, Lan LB, Kim JW, Wei Wang X, Relling MV, Kazuto Y, Watkins PB, Strom S, Sun D, Schuetz JD, Schuetz EG. Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. Pharmacogenet Genomics 2006, 16(6):415-427.
31. Braeuning A, Sanna R, Huelsken J, Schwarz M. Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specific knockout of Ctnnb1. Drug Metab Dispos 2009, 37(5):1138-1145.
32. Bars RG, Elcombe CR. Dose-dependent acinar induction of cytochromes P450 in rat liver. Evidence for a differential mechanism of induction of P450IA1 by beta-naphthoflavone and dioxin. Biochem J 1991, 277(Pt 2):577-580.
33. Oinonen T, Saarikoski S, Husgafvel-Pursiainen K, Hirvonen A, Lindros KO. Pretranslational induction of cytochrome P4501A enzymes by beta-naphthoflavone and 3-methylcholanthrene occurs in different liver zones. Biochem Pharmacol 1994, 48(12):2189-2197.
34. Fritz P, Behrle E, Beaune P, Eichelbaum M, Kroemer HK. Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase. Histochemistry 1993, 99(6):443-451.
35. Garcia-Alcalde F, Garcia-Lopez F, Dopazo J, Conesa A. Paintomics: a web based tool for the joint visualization of transcriptomics and metabolomics data. Bioinformatics 2011, 27(1):137-139.
36. Huang K, Zhang JX, Han L, You YP, Jiang T, Pu PY, Kang CS. MicroRNA roles in beta-catenin pathway. Mol Cancer 2010, 9:252.
37. Braeuning A. Regulation of cytochrome P450 expression by Ras- and beta-catenin-dependent signaling. Curr Drug Metab 2009, 10(2):138-158.
38. Haussinger D. Liver glutamine metabolism. JPEN J Parenter Enteral Nutr 1990, 14(4 Suppl):56S-62S.
39. Baudoin R, Griscom L, Prot JM, Legallais C, Leclerc E. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor. Biochemical Engineering Journal 2011, 53(2):172-181.
40. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2000, 2(9):653-660.
41. Goasduff T, Cederbaum AI. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90. Arch Biochem Biophys 2000, 379(2):321-330.
42. He B, Qiu X, Li P, Wang L, Lv Q, Shi T. HCCNet: an integrated network database of hepatocellular carcinoma. Cell Res 2010, 20(6):732-734.
43. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999, 4(6):1029-1040.
44. Dixit A, Verkhivker GM. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol 2009, 5(8):e1000487.
45. Cheng S, Niv MY. Molecular dynamics simulations and elastic network analysis of protein kinase B (Akt/PKB) inactivation. J Chem Inf Model 2010, 50(9):1602-1610.
46. Miyake S, Lupher ML, Druker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci USA 1998, 95(14):7927-7932.
47. Attisano L, Wrana JL. Signal Transduction by the TGF-β Superfamily. Science 2002, 296(5573):1646-1647.
48. Gebhardt R, Hovhannisyan A. Organ patterning in the adult stage: the role of Wnt/beta-catenin signaling in liver zonation and beyond. Dev Dyn 2010, 239(1):45-55.
49. Mavri-Damelin D, Eaton S, Damelin LH, Rees M, Hodgson HJ, Selden C. Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. Int J Biochem Cell Biol 2007, 39(3):555-564.
50. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9(1):28-39.